Fig 1.
Strategy of diagnostic target selection.
(A) Each step of the workflow analysis was numbered according to the strategy used for target selection. (B) Schematic representation of the relational database developed to integrate data obtained after computational predictions. (C) Number of proteins selected after each step from (A).
Table 1.
Schistosoma mansoni proteins selected after in silico analysis, according to the strategy outlined in the workflow.
Table 2.
Epitopes selected to be used as synthetic peptides in ELISA test.
Fig 2.
Human IgG-specific response against synthetic peptides from S. mansoni targeted for use in diagnosis.
Serum samples were collected from 51 individuals living in an area of low endemicity for S. mansoni infection. Samples from 25 individuals with negative stool examination (NEG) and from 26 individuals with positive stool examination were evaluated (INF). Sera from patients treated 30 and 180 days after treatment were also evaluated. Additionally, sera from 13 healthy donors (HD) not living in an endemic area for schistosomiasis were used as a negative control. Significant differences between groups are indicated in the graphic. Dashed lines represent the cutoff in the absorbance level which determines specificity and sensitivity.